Application
Docetaxel has been used:to test its effect on lysosomal autophagic flux in gastric cancer cellsin combination with stearidonic acid (SDA) to increase its efficacy and enhancing cell death in human prostate cancer cellsas a microtubule-stabilizing agent in prostate and cervical cancer cellsin combination with a γ-secretase inhibitor (GSI) in prostate cancer stem-like cells (PCSCs) to test its effect on the notch signaling pathway
Biochem/physiol Actions
Docetaxel is a taxane anti-cancer agent related to paclitaxel. It binds to and stabilizes the β−tubulin subunit of microtubules, preventing depolymerization of the mitotic spindle thus leading to cell cycle arrest and apoptosis.
Docetaxel (DOC) is an anti-microtubule agent , a standard anti-cancer drug used in first-line chemotherapy treatment in many types of cancer including prostate and breast cancer. It elicits a stronger effect of inhibiting angiogenesis in both in vitro and in vivo by acting on vascular endothelial growth factor (VEGF) associated with tumor cells. Being involved in many key cellular processes such as cell cycle, angiogenesis, and gene expression; docetaxel interacts with many signaling pathways, such as the epidermal growth factor receptor (EGFR) pathway, Ras pathway, etc.
General description
Docetaxel is a cytotoxic, semisynthetic, second-generation taxane derived from the needles of the European yew tree , with a baccatin ring , and is an anthracycline antibiotic. It is related to paclitaxel but structurally it differs from paclitaxel on the 3′ position of the side chain and 10′ position of the baccatin ring.
Packaging
Bottomless glass bottle. Contents are inside inserted fused cone.
This product has met the following criteria: